Skip to main navigation

Heartflow One
Why CCTA
- CCTA Advantage
- Clinical Evidence
For Patients
About
- About Us
- Newsroom
- Careers
- Contact
Investors
Login
language
- United States
- Japan

Heartflow One
Why CCTA
- CCTA Advantage
- Clinical Evidence
For Patients
About
- About Us
- Newsroom
- Careers
- Contact
Investors
Login
language
- United States
- Japan

Investor Relations

Overview
News & Events
Stock Information
- Stock Information
- Historical Price Lookup
- Stock Information
- Historical Price Lookup
Corporate Governance
Financial Information
IR Resources

Overview
News & Events
Stock Information
- Stock Information
- Historical Price Lookup
Corporate Governance
Financial Information
IR Resources

Annual Reports

Show all

More content are coming soon.

Investor Contact

Nick Laudico
Vice President, Investor Relations
nlaudico@heartflow.com

Subscribe to our email alerts

Heartflow One

Platform Overview
Roadmap Analysis
FFR<sub>CT</sub> Analysis
Plaque Analysis
Support

Why CCTA

CCTA Advantage
Clinical Evidence

For Patients

Patient Stories
Understanding CAD
Why Heartflow

About

About Us
Newsroom
Careers
Contact

Investors

Login

Lang

United States
Japan

Twitter
LinkedIn
Youtube
Heartflow App

Indications
Privacy Policy
Terms of Use
Modern Slavery Statement
Carbon Reduction Plan
Accessibility
Sitemap

Heartflow Analysis consists of four main functions; FFR_CT, Planner, Roadmap, and Plaque. All four functions are cleared for clinical use in the United States, Bahrain, Israel, Saudi Arabia and the United Arab Emirates. Only FFR_CT and Planner functions are cleared for clinical use in Europe, United Kingdom, Australia, Canada, and Japan. Please see Heartflow Analysis Indications for Use and Instructions for Use for more information.

© 2026 Heartflow, Inc. | Heartflow and the Heartflow logo are registered trademarks of Heartflow, Inc. Additionally, Roadmap is claimed as a trademark of Heartflow, Inc. www.heartflow.com | 331 E Evelyn Ave, Mountain View, CA 94041